Hypericin Exerts Detrimental Effect on Huh-7 As a Delegacy of Hepatocellular Carcinoma: A P53 Dependent Pathway
AbstractBackground: Hepatocellular carcinoma is the most common type of liver cancer which arises from the main cells in the liver. We address many studies investigating anti-cancer role of hypericin, however the proposing corresponding molecular pathway seems to be still a debate. Therefore, the present study aimed to evaluate the apoptotic effect of hypericin on the Huh7 as the liver cancer cell line and its relation with the gate keeper gene P53. Materials and Methods: In this study, the Huh7 cell line and fibroblast cells (as control group) were treated with different concentrations of hypericin for 24 and 48 hours. Detection of cell death was performed by MTT assay and flow cytometry. The expression of bax, bcl2 and p53 mRNAs was evaluated by Real-time PCR. Also, Immunocytochemistry (ICC) analysis was used for further evaluation of P53expression. Results: The results showed that hypericin has a dose-dependent cytotoxic effect on the Huh7 cell line, with no or marginal effect on fibroblastic cells. According to flow cytometry results, about 53%cells underwent apoptosis after exposure to LD50 of hypericin for 24 hours. Real-time PCR data demonstrated that the pro-apoptotic genes Bax and P53 expression level increased. Expectedly ICC results confirmed the up-regulation of P53 proteins in treated samples. Conclusion: Our results indicate the cytotoxicity of hypericin on Huh7 cells by affecting the expression of the gate keeper gene P53; furthermore it is suggested that this herb can be utilized simultaneously with modalities targeting P53 up-regulation or related molecular pathways. [GMJ.2020;9:e1896]
Zhao J, Fu Y, Wu J, Li J, Huang G, Qin L. The diverse mechanisms of miRNAs and lncRNAs in the maintenance of liver cancer stem cells. Biomed Res Int. 2018;2018.
Shrestha A. Liver Cancer in Nepal. Euroasian J Hepatogastroenterol. 2018;8(1):63.
Rabinel P, Dousse D, Muscari F, Suc B. Management of liver cancer. The Surgeon's point of view. Rep Pract Oncol Radiother. 2017;22(2):176-80.
Sia D, Villanueva A, Friedman SL, Llovet JM. Liver cancer cell of origin, molecular class, and effects on patient prognosis. Gastroenterology. 2017;152(4):745-61.
Yu LX, Schwabe RF. The gut microbiome and liver cancer: mechanisms and clinical translation. Nat Rev Gastroenterol Hepatol. 2017;14(9):527.
Mitchell JK, Lemon SM, McGivern DR. How do persistent infections with hepatitis C virus cause liver cancer? Curr Opin Virol. 2015;14:101-8.
Bressac B, Puisieux A, Kew M, Volkmann M, Bozcall S, Mura JB et al. p53 mutation in hepatocellular carcinoma after aflatoxin exposure. Lancet. 1991;338(8779):1356-9.
Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006;24(26):4293-300.
Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer. 2006;6(9):674.
Wang Z, Li Z, Ye Y, Xie L, Li W. Oxidative stress and liver cancer: etiology and therapeutic targets. Oxid Med Cell Longev. 2016;2016.
Gamasaee NA, Radmansouri M, Ghiasvand S, Shahriari F, Marzouni HZ, Aryan H et al. Hypericin induces apoptosis in MDA-MB-175-VII cells in lower dose compared to MDA-MB-231. Arch Iran Med. 2018;21(9):387-92.
Ghiassi-Nejad Z, Tarchi P, Moshier E, Ru M, Tabrizian P, Schwartz M et al. Prognostic factors and patterns of Locoregional failure after surgical resection in patients with cholangiocarcinoma without adjuvant radiation therapy: optimal field Design for Adjuvant Radiation Therapy. Int J Radiat Oncol Biol Phys. 2017;99(4):805-11.
Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology. 2016;150(4):835-53.
Javidi MA, Zolghadr F, Babashah S, Sadeghizadeh M. Introducing dendrosomal nanocurcumin as a compound capable of in vitro eliminating undifferentiated stem cells in cell therapy practices. Exp Clin Endocrinol Diabetes. 2015;123(10):632-6.
Mirmalek SA, Jangholi E, Jafari M, Yadollah-Damavandi S, Javidi MA, Parsa Y et al. Comparison of in vitro cytotoxicity and apoptogenic activity of magnesium chloride and cisplatin as conventional chemotherapeutic agents in the MCF-7 cell line. Asian Pac J Cancer Prev. 2016;17(S3):131-4.
Jaradat NA, Al-Ramahi R, Zaid AN, Ayesh OI, Eid AM. Ethnopharmacological survey of herbal remedies used for treatment of various types of cancer and their methods of preparations in the West Bank-Palestine. BMC Complement Altern Med. 2016;16(1):93.
Ting CT, Kuo CJ, Hu HY, Lee YL, Tsai TH. Prescription frequency and patterns of Chinese herbal medicine for liver cancer patients in Taiwan: a cross-sectional analysis of the National Health Insurance Research Database. BMC Complement Altern Med. 2017;17(1):118.
Kirakosyan A, Sirvent TM, Gibson DM, Kaufman PB. The production of hypericins and hyperforin by in vitro cultures of St. John's wort (Hypericum perforatum). Biotechnol Appl Biochem. 2004;39(1):71-81.
Wurglics M, Schubert-Zsilavecz M. Hypericum perforatum: A 'modern'herbal antidepressant. Clin Pharmacokinet. 2006;45(5):449-68.
Zhai XJ, Chen F, Chen C, Zhu CR, Lu YN. LC-MS/MS based studies on the anti-depressant effect of hypericin in the chronic unpredictable mild stress rat model. J Ethnopharmacol. 2015;169:363-9.
Süntar I, Oyardı O, Akkol EK, Ozçelik B. Antimicrobial effect of the extracts from Hypericum perforatum against oral bacteria and biofilm formation. Pharm Biol. 2016;54(6):1065-70.
Mirmalek SA, Azizi MA, Jangholi E, Yadollah-Damavandi S, Javidi MA, Parsa Y et al. Cytotoxic and apoptogenic effect of hypericin, the bioactive component of Hypericum perforatum on the MCF-7 human breast cancer cell line. Cancer Cell Int. 2015;16(1):3.
Momekov G, Ferdinandov D, Zheleva-Dimitrova D, Nedialkov P, Girreser U, Kitanov G. Cytotoxic effects of hyperatomarin, a prenylated phloroglucinol from Hypericum annulatum Moris subsp. annulatum, in a panel of malignant cell lines. Phytomedicine. 2008;15(11):1010-5.
Schempp CM, Kirkin V, Simon-Haarhaus B, Kersten A, Kiss J, Termeer CC B et al. Inhibition of tumour cell growth by hyperforin, a novel anticancer drug from St. John's wort that acts by induction of apoptosis. Oncogene. 2002;21(8):1242.
Song S, Xiong C, Zhou M, Lu W, Huang Q, Ku G et al. Small-animal PET of tumor damage induced by photothermal ablation with 64Cu-bis-DOTA-hypericin. J Nucl Med. 2011;52(5):792-9.
Mirmalek SA, Azizi MA, Jangholi E, Yadollah-Damavandi S, Javidi MA, Parsa Y et al. Cytotoxic and apoptogenic effect of hypericin, the bioactive component of Hypericum perforatum on the MCF-7 human breast cancer cell line. Cancer Cell Int. 2015;16(1):1-9.
Hamilton HB, Hinton DR, Law RE, Gopalakrishna R, Su YZ, Chen ZH et al. Inhibition of cellular growth and induction of apoptosis in pituitary adenoma cell lines by the protein kinase C inhibitor hypericin: potential therapeutic application. J Neurosurg. 1996;85(2):329-34.
Kim JI, Park JH, Park HJ, Choi SK, Lee KT. Induction of differentiation of the human histocytic lymphoma cell line U-937 by hypericin. Arch Pharm Res. 1998;21(1):41-5.
Acar M, Ocak Z, Erdogan K, Cetin EN, Hatipoglu OF, Uyeturk U et al. The effects of hypericin on ADAMTS and p53 gene expression in MCF-7 breast cancer cells. Cancer. 2014;3:5.
Jendželovský R, Mikeš J, Souček K, Procházková J, Kello M, Sačková V et al. Drug efflux transporters, MRP1 and BCRP, affect the outcome of hypericin-mediated photodynamic therapy in HT-29 adenocarcinoma cells. Photochem Photobiol Sci. 2009;8(12):1716-23.
Eriksson ES, Eriksson LA. Identifying the sarco (endo) plasmic reticulum Ca 2+ ATPase (SERCA) as a potential target for hypericin-a theoretical study. Phys Chem Chem Phys. 2012;14(36):12637-46.
Barliya T, Mandel M, Livnat T, Weinberger D, Lavie G. Degradation of HIF-1alpha under hypoxia combined with induction of Hsp90 polyubiquitination in cancer cells by hypericin: a unique cancer therapy. PloS One. 2011;6(9):e22849.
Peebles KA, Baker RK, Kurz EU, Schneider BJ, Kroll DJ. Catalytic inhibition of human DNA topoisomerase IIα by hypericin, a naphthodianthrone from St. John's wort (Hypericum perforatum). Biochem Pharmacol. 2001;62(8):1059-70.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution 4.0 International License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).